组合型人工肾改善维持性血液透析患者失眠的疗效

发布时间：2018-01-09 06:28

本文关键词：组合型人工肾改善维持性血液透析患者失眠的疗效　出处：《实用医学杂志》2015年04期 　论文类型：期刊论文

【摘要】：目的:探讨组合型人工肾对改善维持性血液透析(MHD)患者失眠疗效的分析。方法:选取我院MHD失眠患者48例,随机分为组合型人工肾治疗组(血液透析联合血液灌流)和对照组(血液透析治疗),每组24例,共治疗12周,比较两组治疗前及治疗后失眠评分及缓解率、睡眠质量评分、生存质量评分及对血清β2-MG、PTH、hs-CRP等变化。结果 :治疗12周后,组合型人工肾治疗组失眠缓解率(58.3%)明确高于对照组(25.0%),失眠评分及睡眠质量评分明确低于对照组,组合型人工肾治疗组生存质量评分明显高于对照组,两组比较具有显著的统计学差异(P0.01);同时组合型人工肾治疗12周后血清PTH、β2-MG、hsCRP水平明显低于对照组(P0.05)。结论:组合型人工肾可以有效清除血清中PTH、β2-MG、hs-CRP等中大分子毒素及炎症因子,并明显改善MHD患者失眠状况,提高患者睡眠质量及生存质量。
[Abstract]:Objective: to investigate the curative effect of combined artificial kidney on insomnia in patients with maintenance hemodialysis (HD). Methods: 48 patients with MHD insomnia were selected in our hospital. They were randomly divided into two groups: the combined artificial kidney treatment group (hemodialysis combined with hemoperfusion) and the control group (24 patients in each group) for 12 weeks. The scores of insomnia, sleep quality, quality of life and serum 尾 _ 2-MGG _ (PTHH) hs-CRP were compared between the two groups before and after treatment. Results: after 12 weeks of treatment. The remission rate of insomnia in combined artificial kidney group (58.3%) was significantly higher than that in control group (25.0%), and the score of insomnia and sleep quality was lower than that in control group. The quality of life score of combined artificial kidney treatment group was significantly higher than that of the control group, and there was significant statistical difference between the two groups (P 0.01). At the same time, the levels of serum PTH, 尾 2-MGG hsCRP were significantly lower than those of the control group (P 0.05) after 12 weeks of combined artificial kidney therapy. Conclusion: combined artificial kidney can effectively remove PTH in serum. 尾 _ 2-MGG hs-CRP and other macromolecular toxins and inflammatory factors, and significantly improved insomnia in patients with MHD, improve the quality of sleep and quality of life of patients.
【作者单位】：武警辽宁总队大连医院内科;大连医科大学附属第一医院肾内科;
【分类号】：R692.5
【正文快照】： 维持性血液透析(maintenance hemodialysis,MHD)是终末期肾脏病患者的主要治疗方法。随着血液净化技术的改进,MHD患者存活时间明显延长,失眠作为其常见的并发症之一,其发病率也随之增高,严重影响MHD患者生存质量及预后[1]。研究[2]表明睡眠障碍是影响MHD患者生存质量的一个重

【共引文献】